Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease

Exclusion Criteria

• •1. Diagnosis or suspicion of other cause for Parkinsonism.
• •2. Patients unable to attend the clinic visits in the practically defined OFF medication state.
• •3. Body mass index \<18.5.
• •4. Known abnormality on CT or MRI brain imaging considered likely to compromise compliance with trial protocol.
• •5. Significant cognitive impairment defined by a score \<21 on the Montreal Cognitive Assessment.
• •6. Concurrent severe depression defined by a score ≥16 on the Patient Health Questionnaire (PHQ-9).
• •7. Prior intra-cerebral surgical intervention for Parkinson's disease.
• •8. Previous participation in one of the following Parkinson's disease trials (Biogen SPARK trial, Prothena Pasadena trial, Sanofi Genzyme MOVES-PD trial, UDCA-PD UP Study or any other trial still considered to involve a potentially PD modifying agent).
• •9. Participation in another clinical trial of a device, drug or surgical treatment within the last 30 days
• •10. Previous exposure to exenatide.
• •11. Impaired renal function with creatinine clearance \<50ml/min.
• •12. History of pancreatitis.
• •13. Type 1 or Type 2 diabetes mellitus.
• •14. Severe gastrointestinal disease (e.g. gastroparesis)
• •15. Hyperlipidaemia.
• •16. History or family history of medullary thyroid cancer (MTC).
• •17. Multiple endocrine neoplasia 2 (MEN2) syndrome.
• •18. Hypersensitivity to any of exenatide's excipients.
• •19. Females that are pregnant or breast feeding.
• •20. WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire trial period and up to 3 months after the last dose of trial medication.
• •21. Participants who lack the capacity to give informed consent
• •22. Any medical or psychiatric condition or previous conventional/experimental treatment which in the investigator's opinion compromises the potential participant's ability to participate.